Graft Polymer (UK) Plc announced the appointment of Anthony Tennyson as Executive Director with immediate effect. Mr. Tennyson will lead a comprehensive review of the Company's operations, with a particular focus on maximising value from the existing assets, including its novel and patented Graft Bio drug delivery solution. He will lead the Board in identifying opportunities for commercial growth and strategic partnerships.

With a career spanning the life sciences and financial services sectors, Mr. Tennyson brings a wealth of relevant experience to the Company. His position with the Company will be held jointly with his existing employer Awakn Life Sciences Corp. (Awakn), which he co-founded in 2020 and serves as its CEO.

Under Mr. Tennyson's leadership, Awakn successfully navigated public listings on Cboe Canada and the OTCQB in the US, raising CAD 20 million. He also cultivated strategic partnerships with government agencies and leading pharmaceutical companies resulting in licensing agreements for promising phase 2 and phase 1 programmes targeting AUD. Prior to his role at Awakn, Mr. Tennyson held senior roles at Aon Plc where he contributed to the growth and development of Aon's risk consulting business.

He also gained valuable experience of the capital markets at Merrill Lynch and Bank of Ireland. Mr. Tennyson holds an MBA and an MSc from University College Dublin (UCD), Ireland.